🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)

RecruitingPhase 2, Phase 3Ages 2 Years - 16 YearsAllSohag University
NCT07095842 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age from 2 to 16 years. * Established diagnosis of epilepsy of at least 1 year duration. * History of at least 1 episode of convulsive status epilepticus in the preceding 12 months. Exclusion Criteria: * Failure to obtain informed consent. * Known allergies or contraindications to ketamine. * Known contraindications to intramuscular injection. * Presence of another family member included in the same trial. * Having subsequent events (only the index event will be included).
💊

What it tests

  • Ketamine
  • Midazolam
📍

Where

1 site
Department of Pediatrics at Sohag University Hospital
Sohag, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy